JP7810640B2 - 治療用コンジュゲート - Google Patents

治療用コンジュゲート

Info

Publication number
JP7810640B2
JP7810640B2 JP2022516684A JP2022516684A JP7810640B2 JP 7810640 B2 JP7810640 B2 JP 7810640B2 JP 2022516684 A JP2022516684 A JP 2022516684A JP 2022516684 A JP2022516684 A JP 2022516684A JP 7810640 B2 JP7810640 B2 JP 7810640B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
optionally substituted
group
clm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548135A (ja
JPWO2021055747A5 (https=
JP2022548135A5 (https=
Inventor
ソニン ダワン，ニール
アベレラ ブレア，ジェームズ
ビー． ペルニ，ロバート
Original Assignee
トータス メディスンズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トータス メディスンズ インコーポレイテッド filed Critical トータス メディスンズ インコーポレイテッド
Publication of JP2022548135A publication Critical patent/JP2022548135A/ja
Publication of JPWO2021055747A5 publication Critical patent/JPWO2021055747A5/ja
Publication of JP2022548135A5 publication Critical patent/JP2022548135A5/ja
Application granted granted Critical
Publication of JP7810640B2 publication Critical patent/JP7810640B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022516684A 2019-09-19 2020-09-18 治療用コンジュゲート Active JP7810640B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962902554P 2019-09-19 2019-09-19
US62/902,554 2019-09-19
US202063078055P 2020-09-14 2020-09-14
US63/078,055 2020-09-14
PCT/US2020/051491 WO2021055747A1 (en) 2019-09-19 2020-09-18 Therapeutic conjugates

Publications (4)

Publication Number Publication Date
JP2022548135A JP2022548135A (ja) 2022-11-16
JPWO2021055747A5 JPWO2021055747A5 (https=) 2023-09-27
JP2022548135A5 JP2022548135A5 (https=) 2023-09-27
JP7810640B2 true JP7810640B2 (ja) 2026-02-03

Family

ID=74883745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516684A Active JP7810640B2 (ja) 2019-09-19 2020-09-18 治療用コンジュゲート

Country Status (19)

Country Link
US (4) US20220387603A1 (https=)
EP (1) EP4031143B1 (https=)
JP (1) JP7810640B2 (https=)
KR (1) KR20220079866A (https=)
CN (2) CN120789282A (https=)
AU (1) AU2020349543A1 (https=)
BR (1) BR112022005026A2 (https=)
CA (1) CA3154079A1 (https=)
CL (1) CL2022000665A1 (https=)
CO (1) CO2022003703A2 (https=)
DK (1) DK4031143T3 (https=)
ES (1) ES3043134T3 (https=)
IL (1) IL291486B1 (https=)
MX (1) MX2022003217A (https=)
PE (1) PE20230091A1 (https=)
PH (1) PH12022550494A1 (https=)
TW (1) TWI870468B (https=)
WO (1) WO2021055747A1 (https=)
ZA (1) ZA202203201B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체
WO2022198024A1 (en) * 2021-03-18 2022-09-22 Totus Medicines Inc. Therapeutic conjugates
WO2023183936A2 (en) * 2022-03-24 2023-09-28 Totus Medicines Inc. Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
AU2023240100A1 (en) 2022-03-24 2024-10-03 Totus Medicines Inc. Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2024086664A2 (en) * 2022-10-18 2024-04-25 Totus Medicines Inc. Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof
WO2024220380A2 (en) * 2023-04-16 2024-10-24 Totus Medicines Inc. Pi3k assays and probe compounds therein
EP4704841A1 (en) 2023-05-05 2026-03-11 Eli Lilly and Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
CN117126164B (zh) * 2023-08-30 2024-09-27 山东轩硕医药科技有限公司 一种吡咯并三嗪类化合物，其制备方法及用途
WO2025072796A1 (en) * 2023-09-27 2025-04-03 Totus Medicines Inc. Pharmaceutical compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518010A (ja) 2012-05-31 2015-06-25 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途
WO2018233684A1 (zh) 2017-06-23 2018-12-27 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
AU2011258005A1 (en) 2010-05-28 2013-01-17 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as Janus kinase inhibitors
US20120231963A1 (en) 2011-03-10 2012-09-13 Raybiotech, Inc, Biotin-label-based antibody array for high-content profiling of protein expression
CA2836449C (en) * 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
KR102420322B1 (ko) 2014-06-17 2022-07-13 키에시 파르마슈티시 엣스. 피. 에이. 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체
ES2771926T3 (es) * 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US12291533B2 (en) 2017-08-02 2025-05-06 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
CN109081905A (zh) 2018-08-03 2018-12-25 浩力森涂料（上海）有限公司 水性环氧固化剂及其制备方法
WO2020052772A1 (en) 2018-09-13 2020-03-19 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Modulation of trf1 for brain cancer treatment
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
KR20220079866A (ko) 2019-09-19 2022-06-14 토투스 메디신스 아이엔씨. 치료 접합체
EP4165045A4 (en) 2020-06-05 2024-07-03 Monash University DOUBLE KINASE-BROMODOMAIN INHIBITORS
US20230285498A1 (en) 2020-08-07 2023-09-14 City Of Hope Treatments for cancers having kras mutations
WO2022198024A1 (en) 2021-03-18 2022-09-22 Totus Medicines Inc. Therapeutic conjugates
WO2023183936A2 (en) 2022-03-24 2023-09-28 Totus Medicines Inc. Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
AU2023240100A1 (en) 2022-03-24 2024-10-03 Totus Medicines Inc. Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518010A (ja) 2012-05-31 2015-06-25 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ピロロ［２，１−ｆ］［１，２，４］トリアジン系化合物、その製造方法および用途
WO2018233684A1 (zh) 2017-06-23 2018-12-27 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途

Also Published As

Publication number Publication date
CN120789282A (zh) 2025-10-17
CA3154079A1 (en) 2021-03-25
CN114599366B (zh) 2025-05-09
JP2022548135A (ja) 2022-11-16
TWI870468B (zh) 2025-01-21
US20240366771A1 (en) 2024-11-07
US20220211855A1 (en) 2022-07-07
US20230096658A1 (en) 2023-03-30
MX2022003217A (es) 2022-06-29
IL291486A (en) 2022-05-01
US12029791B2 (en) 2024-07-09
KR20220079866A (ko) 2022-06-14
CL2022000665A1 (es) 2022-10-28
ES3043134T3 (en) 2025-11-24
EP4031143A4 (en) 2023-11-01
CO2022003703A2 (es) 2022-07-08
IL291486B1 (en) 2026-03-01
US11484597B2 (en) 2022-11-01
AU2020349543A1 (en) 2022-03-24
EP4031143A1 (en) 2022-07-27
EP4031143B1 (en) 2025-07-30
DK4031143T3 (da) 2025-10-13
WO2021055747A1 (en) 2021-03-25
PE20230091A1 (es) 2023-01-16
US20220387603A1 (en) 2022-12-08
BR112022005026A2 (pt) 2022-06-21
CN114599366A (zh) 2022-06-07
PH12022550494A1 (en) 2023-02-27
TW202126307A (zh) 2021-07-16
ZA202203201B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
JP7810640B2 (ja) 治療用コンジュゲート
EP4308121A1 (en) Therapeutic conjugates
EP3298015B1 (en) Pyrazolopyrimidine derivatives
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
WO2022056453A1 (en) Therapeutic conjugates
HK40068429B (en) Therapeutic conjugates
HK40068429A (en) Therapeutic conjugates
JP2009504692A (ja) 新規４−アミノ−チエノ［３，２−ｃ］ピリジン−７−カルボン酸アミド
US20220370625A1 (en) Therapeutic conjugates
EP4676600A1 (en) Protein kinase inhibitors and uses thereof
WO2024220380A2 (en) Pi3k assays and probe compounds therein
WO2026050773A1 (en) Protein kinase inhibitors and uses thereof
EP4676601A1 (en) Protein kinase inhibitors and uses thereof
WO2023192328A1 (en) An oxaziridine platform for targeting functional allosteric methionine sites
WO2021092892A1 (zh) 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用
HK1175778B (en) Process for preparing a 5h-pyrimido[5,4-d][2]benzazepine
HK1175778A1 (en) Process for preparing a 5h-pyrimido[5,4-d][2]benzazepine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260122

R150 Certificate of patent or registration of utility model

Ref document number: 7810640

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150